Important Information for Intellia Therapeutics, Inc. (NTLA) Investors: Rosen Law Firm Announces Securities Class Action Lawsuit and Lead Plaintiff Deadline
NEW YORK, March 05, 2025
Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Intellia Therapeutics, Inc. (NASDAQ: NTLA) between July 30, 2024 and January 8, 2025, both dates inclusive (the “Class Period”), of the important April 14, 2024 lead plaintiff deadline. The lawsuit alleges that Intellia Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that:
- The company’s CRISPR/Cas9 gene-editing technology, which was the basis for its therapeutic programs, was not as effective as the company had represented;
- The company’s CRISPR/Cas9 gene-editing technology had significant safety concerns;
- The company had not achieved the successes it had claimed in its clinical trials;
- The company’s financial statements were not accurate, and;
- The company’s executives had made false and misleading statements regarding the company’s business and financial condition.
What Does This Mean for Intellia Therapeutics, Inc. (NTLA) Investors?
If you purchased Intellia Therapeutics, Inc. securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is April 14, 2024. The lead plaintiff is the representative party in the class action and the individual or entity that will represent the interests of the class in the litigation. Your ability to share in any recovery doesn’t require you to serve as the lead plaintiff. To be a class member, you need only to have purchased Intellia Therapeutics, Inc. securities during the Class Period. The class has until April 14, 2024, to move the Court to serve as the lead plaintiff.
What Does This Mean for the World?
The gene-editing industry, particularly the CRISPR/Cas9 technology, has been a subject of intense interest and investment in recent years. Intellia Therapeutics, Inc.’s announcement of its gene-editing technology’s ineffectiveness and safety concerns could have significant implications for the entire industry. This lawsuit could lead to increased scrutiny of the gene-editing industry and potentially result in changes to regulatory requirements and standards. It could also impact investor confidence in the industry and individual companies.
Conclusion
If you purchased Intellia Therapeutics, Inc. securities during the Class Period, you may be entitled to compensation. The lead plaintiff deadline is April 14, 2024. This lawsuit could lead to significant changes for the gene-editing industry and impact investor confidence. It is essential for investors to stay informed and seek professional advice regarding their investment options.
If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Phillip Kim, Esq. of Rosen Law Firm at [email protected] or (212) 686-1060, or submit the form on the firm’s website at www.rosenlegal.com/cases-registered-1625.html for more information.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. The firm was Ranked No. 1 in the number of securities class action settlements in 2019 and 2020 according to ISS Securities Class Action Services.
Follow us on Twitter: @RosenLawFirm or on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm for announcements about this and other litigation.
ATTORNEY ADVERTISING. The Rosen Law Firm is not licensed in all jurisdictions. We provide legal services for clients throughout the globe, but the protection of investor rights and securities laws of various jurisdictions may differ.
